Glen Eagle Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Glen Eagle Advisors’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-300	Closed	-$10.3K	–	1016
2022 Q1	$10.3K	Hold	300	–	–	﹤0.01%	616
2021 Q4	$13.1K	Hold	300	–	–	﹤0.01%	574
2021 Q3	$15.2K	Hold	300	–	–	﹤0.01%	608
2021 Q2	$15.6K	Hold	300	–	–	﹤0.01%	602
2021 Q1	$13.7K	Hold	300	–	–	﹤0.01%	602
2020 Q4	$13.8K	Buy	300 +100	+50%	+$4.32K	0.01%	571
2020 Q3	$7.79K	Hold	200	–	–	﹤0.01%	637
2020 Q2	$7.59K	Hold	200	–	–	﹤0.01%	607
2020 Q1	$5.37K	Buy	+200	New	+$5.68K	﹤0.01%	608

Other funds holding IDNA

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nomura Asset Management Tokyo, Japan $38.8B AUM 30.94% 1-Year Est. Return

Glen Eagle Advisors's IDNA Position: Q2 2022 in Review

Glen Eagle Advisors sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q2 2022, closing a stake of 300 shares — an estimated $10.3K sold.

Glen Eagle Advisors first reported a position in IDNA in Q1 2020 and held it in 9 quarters. The position peaked at $15.6K in Q2 2021. 73 funds tracked by Wall St. Rank hold IDNA as of Q2 2022.

Glen Eagle Advisors reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q2 2022 after selling out during the quarter.
Glen Eagle Advisors sold 300 iShares Genomics Immunology and Healthcare ETF shares in Q2 2022, an estimated $10.3K.
Glen Eagle Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2020 and held it in 9 quarters.
Glen Eagle Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $15.6K in Q2 2021.
73 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2022.

Based on Glen Eagle Advisors's 13F filing for Q2 2022, filed 13 Aug 2024.